171333

FAQ's

Answer : According to Precedence Research, the global conjunctivitis market size was reached at USD 4.55 billion in 2021 and is projected to hit over USD 6.31 billion by 2030.

Answer : The global conjunctivitis market is exhibiting at a CAGR of 3.65% during forecast period 2022 to 2030.

Answer : Factors such as increasing prevalence of conjunctivitis, increasing healthcare expenditure, rising exposure to allergens, highly contagious nature of conjunctivitis are driving the growth of conjunctivitis market. Moreover, Additional features that are expected to fuel this business are integration of latest technologies and growing investment by major players.

Answer : In 2020, the North America region dominated the worldwide market with a market share of higher than 43%.

Answer : The Asia Pacific region is projected to grow at the highest CAGR of around 5.35% in the estimate period due to increasing healthcare expenditure.

Answer : Among the type segment, allergic conjunctivitis dominated the overall market in 2020. High prevalence of allergic conjunctivitis due to high exposure to allergen is the foremost factors attributing to its large market share.

Answer : The key companies functioning in the worldwide conjunctivitis market are Atopix Therapeutics Ltd., Allegran, Ocular Therapeutix, Inc., Santen Pharmaceutical Co. Ltd., Novartis, Boehringer Ingelheim, Pfizer Inc, Allegran, Sun Pharma, and Sirion Therapeutics, Inc. among others.

Answer : Conjunctivitis is a contamination of the conjunctiva, a slim membrane layering the white portion of the sclera, eye, or the internal surface of the lids. Conjunctivitis can be very contagious and expand easily within large collections of people. Occasionally, especially in children, the ailment can affect visualization. In such situations, clinicians need to be knowledgeable immediately for effective and primary treatment.